Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant

Clinical and Vaccine Immunology

Volumn 18, Issue 7, 2011, Pages 1167-1175

  Hamouda, Tarek ^a   Sutcliffe, Joyce A ^a,b   Ciotti, Susan ^a   Baker Jr , James R ^a  

^a NanoBio Corporation   (United States)

^b TetraPhase Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; NB 1008; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; FERRET; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA VACCINATION; MALE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; TH1 CELL; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; CROSS REACTIONS; EMULSIONS; FERRETS; IMMUNITY, CELLULAR; IMMUNIZATION; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 79960120763     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00035-11     Document Type: Article

References (33)

1. Atmar, R. L., et al. 2007. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25:5367-5373. (Pubitemid 46977533)
2. Belshe, R. B., K. Coelingh, C. S. Ambrose, J. C. Woo, and X. Wu. 2010. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28:2149-2156.
3. Belshe, R. B., et al. 2000. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136:168-175. (Pubitemid 30470986)
4. Belshe, R. B., et al. 1998. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 338:1405-1412.
5. Beyer, W. E., I. A. de Bruijn, A. M. Palache, R. G. Westendorp, and A. D. Osterhaus. 1998. The plea against annual influenza vaccination? 'The Hoskins' paradox' revisited. Vaccine 16:1929-1932.
6. Beyer, W. E., A. M. Palache, J. C. de Jong, and A. D. Osterhaus. 2002. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20:1340-1353.
7. Bielinska, A. U., et al. 2008. A novel, killed-virus nasal vaccinia virus vaccine. Clin. Vaccine Immunol. 15:348-358.
8. Bielinska, A. U., et al. 2007. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun. 75:4020-4029.
9. Bielinska, A. U., et al. 2008. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 24:271-281.
10. Boyce, T. G., et al. 1999. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 18:82-88. (Pubitemid 29432141)
11. Cate, T. R., R. B. Couch, J. A. Kasel, and H. R. Six. 1977. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J. Infect. Dis. 136(Suppl.):S450-S455.
12. Cate, T. R., R. B. Couch, D. Parker, and B. Baxter. 1983. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev. Infect. Dis. 5:737-747.
13. Clements, M. L., R. F. Betts, E. L. Tierney, and B. R. Murphy. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160.
14. Couch, R. B. 2008. Seasonal inactivated influenza virus vaccines. Vaccine 26(Suppl. 4):D5-D9.
15. De Magistris, M. T. 2006. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev. 58:52-67.
16. Doherty, P. C., S. J. Turner, R. G. Webby, and P. G. Thomas. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7:449-455.
17. Ghendon, Y. 1994. Influenza vaccines: a main problem in control of pandemics. Eur. J. Epidemiol. 10:485-486.
18. Guan, Y., et al. 2004. H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. U. S. A. 101:8156-8161.
19. Gupta, R. K., et al. 1993. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11:293-306. (Pubitemid 23061171)
20. Hamouda, T., et al. 2010. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum. Vaccin. 6:585-594.
21. Kohn, M. A., et al. 1995. Three summertime outbreaks of influenza type A. J. Infect. Dis. 172:246-249.
22. Lui, K. J., and A. P. Kendal. 1987. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 77:712-716.
23. Makidon, P. E., et al. 2008. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 3:e2954.
24. Mossad, S. B. 2003. Demystifying FluMist, a new intranasal, live influenza vaccine. Cleve. Clin. J. Med. 70:801-806.
25. Myc, A., et al. 2003. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 21:3801-3814. (Pubitemid 37338208)
26. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (London) 27:493-497.
27. Salk, J. E., W. J. Menke, and T. J. Francis. 1945. A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am. J. Epidemiol. 42:57-93.
28. Schild, G. C., J. M. Wood, and R. W. Newman. 1975. A single-radial- immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull. World Health Organ. 52:223-231.
29. Stephenson, I., and M. Zambon. 2002. The epidemiology of influenza. Occup. Med. (London) 52:241-247.
30. Sweet, C., and H. Smith. 1980. Pathogenicity of influenza virus. Microbiol. Rev. 44:303-330.
31. Webster, R., N. Cox, and K. Stohr. 2002. WHO manual on animal influenza diagnosis and surveillance. WHO Global Influenza Programme, WHO, Geneva, Switzerland.
32. WHO. 12 March 2010, posting date. Pandemic (H1N1) 2009 - update 91. Weekly virological surveillance update. WHO, Geneva, Switzerland. http://www.who.int/csr/disease/swineflu/laboratory12-03-2010/en/index.html.
33. Wood, J. M., G. C. Schild, R. W. Newman, and V. Seagroatt. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5:237-247.